Rhinomed (ASX:RNO) Accounts Payable & Accrued Expense : A$2.56 Mil (As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Rhinomed Accounts Payable & Accrued Expense?

Rhinomed's quarterly accounts payable & accrued expense increased from Jun. 2022 (A$2.67 Mil) to Dec. 2022 (A$3.35 Mil) but then declined from Dec. 2022 (A$3.35 Mil) to Jun. 2023 (A$2.56 Mil).

Rhinomed's annual accounts payable & accrued expense increased from Jun. 2021 (A$1.07 Mil) to Jun. 2022 (A$2.67 Mil) but then declined from Jun. 2022 (A$2.67 Mil) to Jun. 2023 (A$2.56 Mil).

Rhinomed Accounts Payable & Accrued Expense Historical Data

The historical data trend for Rhinomed's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhinomed Accounts Payable & Accrued Expense Chart

Rhinomed Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

0.60

0.56

1.07

2.67

2.56

Rhinomed Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															1.07	2.09	2.67	3.35	2.56

Rhinomed Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Rhinomed (ASX:RNO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rhinomed Ltd (ASX:RNO) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

RHNMF:USA

Address

132 Gwynne Street, Level 1, Cremorne, VIC, AUS, 3121

Website

https://www.rhinomed.global

Rhinomed Ltd is a medical technology company, with a patented nasal technology platform. It is engaged in the research, development and commercialization of consumer and medical devices including nasal, respiratory and nasal drug delivery technologies. It operates in one segment which is the identification, acquisition, and commercialization of late-stage consumer therapeutic and medical delivery technologies. The products of the company involve Rhinoswab, Mute, Turbine and Rhinoswab Junior. It operates geographically within North, Central, and South America, Asia-Pacific, Europe, Middle East, and Africa. The company earns majority of its revenue from Asia-Pacific.

Rhinomed (ASX:RNO) Headlines

No Headlines